LB 77.61 L Brands Inc $LB Hit a 52 week high of 77.68

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 11:22 AM

LB 77.61 L Brands Inc $LB Hit a 52 week high of 77.68 Closing the day 09:45 at 77.61 -0.10 -0.13% With a day low of 77.25 and a total volume of 118,418.

LB Recent Posts: http://investorshangout.com/L-Brands-Inc-LB-51712/

LB L Brands Inc Recent Headline News

Home Depot Beats Q3 Earnings Estimates, Retains Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 11 mins ago
The Home Depot Inc. (HD) reported adjusted earnings of $1.15 per share, up nearly 21.1% from the year-ago quarter's earnings of 95 cents while it surpassed the Zacks Consensus Estimate of $1.13.
ZUMZ: 33.49 (-0.49), HD: 96.78 (-1.25), LB: 76.94 (-0.77), LOW: 58.27 (-0.62)

Urban Outfitters Earnings Miss, Namesake Brand Sales Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 21 mins ago
Urban Outfitters (URBN) posted third-quarter fiscal 2015 results, wherein earnings of 35 cents a share missed the Zacks Consensus Estimate of 42 cents and also plunged 25.5% from the year-ago quarter.
URBN: 27.99 (-2.84), ZUMZ: 33.49 (-0.49), LB: 76.94 (-0.77), AEO: 13.21 (-0.13)

Is L Brands (LB) Likely to Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:40AM CST
L Brands (LB), a specialty retailer of women's intimate and other apparel, beauty and personal care products, is slated to report third-quarter fiscal 2014 results on Nov 19.
LB: 76.94 (-0.77), BBY: 34.72 (-0.57), MIK: 22.04 (+0.39), LOW: 58.27 (-0.62)

Will PetSmart (PETM) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 11:30AM CST
Our proven model does not conclusively show that PetSmart, Inc. (PETM) is likely to beat earnings this quarter.
SPLS: 12.75 (-0.22), LB: 76.94 (-0.77), TGT: 66.65 (-0.48), PETM: 72.99 (-0.62)

Is DICK's Sporting (DKS) Likely to Miss Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 10:40AM CST
DICK'S Sporting Goods Inc. (DKS) is slated to release its third-quarter fiscal 2014 results on Nov 18, 2014.
LB: 76.94 (-0.77), DKS: 47.05 (-0.46), GME: 43.91 (-0.19), BBY: 34.72 (-0.57)

Will Urban Outfitters (URBN) Q3 Earnings Miss Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 10:00AM CST
Urban Outfitters (URBN), the specialty retailer of fashion apparel and accessories, footwear, home d??cor and gifts products, is expected to report third-quarter fiscal 2015 results on Nov 17.
URBN: 27.99 (-2.84), LB: 76.94 (-0.77), GME: 43.91 (-0.19), BBY: 34.72 (-0.57)

Dillard's Q3 Earnings Beat Estimates, Outlook Intact - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 9:20AM CST
Dillard's Inc. (DDS) yesterday reported better-than-anticipated third-quarter fiscal 2014 results.
DDS: 108.03 (-1.79), LB: 76.94 (-0.77), COLM: 41.45 (unch), ROST: 80.79 (-0.55)

Nordstrom Reports Strong Q3 Earnings, Updates Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 8:00AM CST
Nordstrom Inc's (JWN) third-quarter earnings of 73 cents per share came ahead of the Zacks Consensus Estimate of 71 cents and in line with company's expectations.
BEBE: 2.61 (+0.03), ZUMZ: 33.49 (-0.49), LB: 76.94 (-0.77), JWN: 72.94 (-0.33)

American Eagle Gains 10% on Upbeat Q3 Earnings Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 2:10PM CST
Shares of American Eagle Outfitters Inc. (AEO) gained over 10% during yesterday's trade after the teen specialty retailer raised its third-quarter fiscal 2014 earnings outlook.
LB: 76.94 (-0.77), AEO: 13.21 (-0.13), COLM: 41.45 (unch), ROST: 80.79 (-0.55)

Starbucks (SBUX) Brings Holiday Drink and Gift Card Options - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:10PM CST
Starbucks Corporation (SBUX) recently launched new holiday beverage choices, the Starbucks Dot collection of drinkware and the first ever uniquely designed Starbucks Card collection just in time to kick off the holiday season.
SBUX: 77.57 (-0.26), LB: 76.94 (-0.77), GME: 43.91 (-0.19), PZZA: 49.19 (+0.23)

Wal-Mart's Q3 Earnings In Line, Sales Beat; View Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 10:12AM CST
After six weak quarters in a row, Wal-Mart Stores Inc.'s (WMT) third quarter fiscal 2015 earnings came in line with estimates, while revenues were better-than-expected. The company however narrowed its guidance for fiscal 2015.
LB: 76.94 (-0.77), SWY: 34.85 (+0.10), CTRN: 22.10 (-0.05), WMT: 83.71 (+0.14)

Kohl's (KSS) Misses on Q3 Earnings, Revenue Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 9:05AM CST
Retailer, Kohl's Corporation (KSS) posted third-quarter fiscal 2014 earnings of 70 cents per share, missing the Zacks Consensus Estimate of 76 cents by 7.9% and prior-year quarter earnings by 14%.
KSS: 56.63 (-0.71), LB: 76.94 (-0.77), DLTR: 61.58 (+0.11), ROST: 80.79 (-0.55)

L Brands Invites You To Listen To Its Third Quarter 2014 Earnings Call Webcast
Thomson Reuters ONE - Thu Nov 13, 8:58AM CST
COLUMBUS, Ohio, Nov. 13, 2014 -- In conjunction with L Brands (NYSE: LB) third quarter 2014 earnings release, which will cross the wire after market close on Wednesday, Nov. 19, you are invited to listen to a live webcast of the conference call on Thursday, Nov. 20, at 9:00 a.m. ET with L Brands executives.
LB: 76.94 (-0.77)

Wal-Mart (WMT) Working to Improve Grocery Offerings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 8:40AM CST
Wal-Mart Stores Inc. (WMT) is focused on improving its grocery offerings, per the reports, as customers find it difficult to get quality fresh food and meat products at affordable prices.
LB: 76.94 (-0.77), SWY: 34.85 (+0.10), CTRN: 22.10 (-0.05), WMT: 83.71 (+0.14)

Fossil Group, Inc. (FOSL) Jumps: Stock Moves 8.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:57AM CST
Fossil Group, Inc. (FOSL) was a big mover last session, as the company saw its shares rise over 8% on the day.
BEBE: 2.61 (+0.03), FOSL: 107.98 (+0.56), LB: 76.94 (-0.77), CTRN: 22.10 (-0.05)

Leggett Sustains Earnings Momentum, Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:20AM CST
Shares of Leggett & Platt Inc. (LEG) reached a new high of $41.53 before closing trade at $41.30.
WHR: 176.71 (+1.16), LB: 76.94 (-0.77), LEG: 41.31 (+0.07), VFC: 72.20 (+0.88)

Fossil Group Beats on Q3 Earnings, Tweaks 2014 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:37AM CST
Fossil Group Inc. (FOSL) reported better-than-expected third quarter 2014 results, but tightened its earnings guidance and slightly lowered revenues and margin expectations for 2014.
FOSL: 107.98 (+0.56), LB: 76.94 (-0.77), CTRN: 22.10 (-0.05), KORS: 73.15 (+0.83)

Zacks Industry Outlook Highlights: Zumiez, L Brands, Buckle, Gap and Fred's
PR Newswire - Wed Nov 12, 8:30AM CST
Today, Zacks Equity Research discusses the Retail, including Zumiez Inc. (Nasdaq:ZUMZ-Free Report), L Brands Inc. (NYSE:LB-Free Report), Buckle Inc. (NYSE:BKE-Free Report), Gap Inc. (NYSE:GPS-Free Report) and Fred's Inc. (Nasdaq:FRED-Free Report).
ZUMZ: 33.49 (-0.49), LB: 76.94 (-0.77), GPS: 39.10 (-0.17), BKE: 48.88 (+0.23)

L Brands: Should You Be A Buyer Before Q3 Earnings Are Announced?
Joey Solitro - at Seeking Alpha - Tue Nov 11, 9:31AM CST

LB: 76.94 (-0.77)

Strong Holiday Season Likely for Retailers? - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:54AM CST
Strong Holiday Season Likely for Retailers? - Industry Outlook
CATO: 36.61 (-0.11), ZUMZ: 33.49 (-0.49), LB: 76.94 (-0.77), FRED: 15.84 (+0.13), GPS: 39.10 (-0.17), BKE: 48.88 (+0.23), WAG: 67.40 (+0.85), RAD: 5.57 (+0.11), SMRT: 13.30 (-0.17)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lassa's Wintus 3: Boosting Winter Tyre Game for 2026

Rolling Through Winter: Lassa's Next Step Ever felt like you were skating on thin ice with your vehicle in winter? That's why Lassa has cranked out the Wintus 3—a tyre making waves in the chilly game. Now, we're not talking about your run-of-the-mill rubber. This is a strategic play by a Turkish powerhouse, Brisa, aimed squarely at those who rely on light commercial...

Dimora Medical Boosts Advanced Wound Care at HS Conference

Empowering the HS Community with Innovations Look, if you’ve walked a mile in someone else's shoes—particularly ones dealing with hidradenitis suppurativa (HS)—you’d know what a relentless grind managing those exuding wounds can be. Dimora Medical, known for navigating the tricky territory of wound care, threw its hat into the ring at the HS Connect Empower...

Solenis Appoints Brendy Lange to Lead Americas Growth

New Leadership at Solenis Change is brewing at Solenis, and it's set to ripple across the water treatment industry like a stone in a pond. Brendy Lange's appointment as Chief Business Officer, Americas, promises to shake things up in a firm as committed to innovation as Solenis. This seasoned executive, scooped from the ranks of Dow Chemical, steps in with a mandate to...

Ractigen's LiCO™ Platform Hits Extrahepatic Milestones

Breaking New Ground in RNA Therapeutics Hey, in the world of biotech, landing a meaningful delivery system is like striking gold, and it seems Ractigen Therapeutics just found a shiny nugget. Their latest study on the LiCO™ platform, living and breathing in the pages of Molecular Therapy - Nucleic Acids, maps out a path to some serious therapeutic territory. These guys...

Galien Recognizes Kerry for Transformative Global Health Work

Kerry's Legacy: A Symbol of Global Unity In the ever-thickening jungle of geopolitics and global health, it's rare to find a beacon as steadfast as John Kerry. This year, The Galien Foundation saw fit to honor him with the 2026 Roy Vagelos Pro Bono Humanum Award for Global Health Equity. This ain't just some shiny trinket—it’s a testament to his lifetime of ripping...

Cboe Clear's US Move: A New Chapter with SEC Nod

Clearing the Path for New Beginnings The ink's barely dry on Cboe Clear U.S.'s recent SEC registration, and it's already setting tongues wagging among market old-timers. This move to clear binary securities options alongside futures isn't just a step up; it's a signal flare for ambitious innovation. The Nuts and Bolts: SEC Registration So, what's the big to-do? Cboe Clear...

Rakuten Medical's Long-Term Data Shows Promise

This Isn't Just Another Cancer Update Alright, folks, let's unwrap what's happening today with Rakuten Medical. They've thrown some serious numbers into the ring at the ESMO Congress 2026 in Madrid. We're talking long-term follow-up results of their ASP-1929 photoimmunotherapy combined with pembrolizumab in tackling recurrent and metastatic head and neck squamous cell...

SAFE Structure Designs Backs Prosthetic Nonprofit 50 Legs

A Partnership Rooted in Service and Faith Let's face it, support from major companies for nonprofits isn't exactly commonplace. But every so often, you run into a partnership that catches your eye, and this one's got a little extra heart. SAFE Structure Designs, known for its defense engineering prowess in Las Vegas, is throwing its weight behind Clearwater's 50 Legs....

S&P Global's New Dashboard: Unpacking Data Insights

An Interactive Take on Digital Infrastructure The geniuses over at S&P Global Ratings have just unleashed a shiny new tool for number crunchers and market hawks who can't get enough data center action—an interactive dashboard. Maybe not everyone’s cup of tea, but hey, in the dog-eat-dog world of digital infrastructure, any edge counts. What's in the Data Center Soup?...

TORL Bio's Ixo-V Drug Shows Promise in Combatting GCT

A Beacon of Hope in Germ Cell Tumor Treatment There's something brewing in the oncology world that's worth a nod. TORL BioTherapeutics has rolled out some interesting preliminary data for their hopeful cancer buster, ixotatug vedotin, or Ixo-V. This study is part of a wider effort to take a swing at recurrent germ cell tumors (GCTs) with some tough results already making...